The article reflects changes in the structure of interventional interventions in patients with acute coronary syndrome in the conditions of the COVID-19 pandemic and suggests changes in the tactics of x-ray endovascular treatment of this category of patients
Objective: to compare the safety of ticagrelor use in patients with STEMI after ineffective thrombolytic treatment (TLT) and successfully performed recanalization of infarct-dependent artery (IDA) by PCI, as ticagrelor loading dose was administered in the time window from TLT to PCI, compared with the TREAT studyresultson the risk of bleeding in real clinical practice.
Materials and methods: a comparative analysis of the results of a 30-day follow-up of 52 patients with acute coronary syndrome with ST-segment elevation who received thrombolytic therapy with alteplasa and early ticagrelor administration with the ticagrelor group in the TREAT study on the parameters of hemorrhagic safety.
Results: arterial hypertension, dyslipidemia, generalized atherosclerosis, chronic obstructive pulmonary disease and a history of myocardial infarction were significantly more common in the study group. Analysis of the results revealed no significant differences between the groups in the frequency and risk of hemorrhagic complications.
Conclusion: there are no significant differences in the frequency of major bleeding according to the TIMI and BARC criteria between the groups, which indicates the safety of early (within 24 hours after thrombolysis) ticagrelor use in the pharmacoinvasive approach in real clinical practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.